Oncology CRO Solutions
Offering Global Oncology CRO Services Focused on Early Phase Oncology Research.
A Leader in Oncology Clinical Trials
ReachCatalyst is a leading oncology and hematology CRO committed to ensuring a smooth journey in the development of your compound. The ReachCatalyst team works tirelessly as an extension of your team to optimize the timeline, conduct, budget, and quality of your oncology clinical study to maximize success.
​
You require a partner that will reliably deliver and assist you in navigating the complexity of oncology clinical trial development and execution. From Phase I-IV, we have optimized our oncology and hematology service offering by dedicating staff, technology, and assets to provide you with reliable and transparent access to data to facilitate decision making. Our robust team member experience ensures exceptional execution in all development operations while offering flexible solutions to meet your specific needs.ReachCatalyst is the dedicated partner you can count on before, during, and after your oncology clinical trial, as we share a common goal of helping your compound succeed.
Early Phase Oncology
ReachCatalyst also differentiates itself from other oncology CROs by excelling in early phase oncology clinical research (Phase I-II). Our unique early phase hematology/oncology collaboration with the HERO Project, leverages our staff, technology, site relationships and processes to improve the efficiency in conduct and reduce the cost of your critically important trials. ReachCatalyst together with HERO (Helping Early Research in Oncology), offers many key features and benefits over the conventional oncology research model, including:
-
Dedicated Early Phase Oncology Teams
-
Strategic Relationships with Phase I Oncology Practices
-
Rapid Study Start-up Process
-
Optimized Clinical Technology Suite
-
Just-in-Time Site Start-up for Rare Cancers
Oncology Clinical Research Expertise
ReachCatalyst offers experienced oncology project teams across the globe ready to support your next hematology/oncology clinical study. Expertise with your specific oncology indication is critically important when selecting the right partner for clinical trial conduct. Having completed over 400 cancer clinical trials, our team is well positioned to leverage their experience to advance your development. Oncology is complex; each indication has its own nuances and challenges to surmount, and selecting the right oncology CRO for your next study requires a partner that can provide focus and dedication to you and your team. We have worked on cancer studies with a diverse range of patient populations and have built a strong network of investigator sites to support these trials. Below is a representation of ReachCatalyst's current oncology clinical research experience by indication:
-
Solid Tumors
-
CAR-T / DAR-T Cell
-
Breast Cancer
-
Lung Cancer
-
Skin Cancer
-
Brain Cancer
-
Prostate Cancer
-
Pancreatic Cancer
-
Gynecological Cancer
-
Hematological Malignancies
-
Neuroendocrine Tumors
-
Cancers of the Gastrointestinal (GI) System
-
Cancers of the Genitourinary (GU) System
-
Cancers of the Head and Neck
-
Pediatric Cancer
-
Quality of Life and Supportive Care
-
Advanced Cancers
-
Other Rare Indications
Tumor-agnostic treatments
The grouping of cancer based on molecular subtypes has changed not only how cancer is categorized but also how novel therapies are investigated in clinical trials. In this blog post, we explore the changing rare oncology landscape and novel approaches to rare cancer trials.
READ MORE
Adaptive trial designs
With the emergence of precision medicine, we are seeing a shift in how early-phase oncology trials are conducted, including a growing number of Phase 1 trials reporting preliminary response rates. This shift is due in part to an increase in adaptive trial designs.